Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Renovaro Biosciences (RENB)
NASDAQ:RENB
Renovaro Biosciences (RENB) Stock Price & Analysis
103 Followers
RENB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.39 - $5.25
Previous Close$2.42
Volume31.35K
Average Volume (3M)313.01K
Market Cap
$333.81M
Enterprise Value$359.14M
Total Cash (Recent Filing)$243.98K
Total Debt (Recent Filing)$7.39M
Price to Earnings (P/E)-3.7
Beta0.24
Next Earnings
May 15, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding143,668,372
10 Day Avg. Volume208,574
30 Day Avg. Volume313,006
Standard Deviation0.55
R-Squared0.00066
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)-32.93
Price to Sales (P/S)1803.59
Price to Cash Flow (P/CF)-28.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue995.90
Enterprise Value/Gross Profit1.02K
Enterprise Value/Ebitda-9.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renovaro Biosciences News
PremiumCompany Announcements
Renovaro Biosciences Appoints Simon Tarsh as Interim CFO
PremiumCompany Announcements
Renovaro Biosciences Faces Key License Agreement TerminationOwnership Overview
60.19% Insiders
0.84% Mutual Funds
2.83% Other Institutional Investors
36.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RENB FAQ
What was Renovaro Biosciences’s price range in the past 12 months?
Renovaro Biosciences lowest stock price was $0.39 and its highest was $5.25 in the past 12 months.
What is Renovaro Biosciences’s market cap?
Currently, no data Available
When is Renovaro Biosciences’s upcoming earnings report date?
Renovaro Biosciences’s upcoming earnings report date is May 15, 2023 which is 356 days ago.
How were Renovaro Biosciences’s earnings last quarter?
Renovaro Biosciences released its earnings results on Feb 13, 2023. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.08.
Is Renovaro Biosciences overvalued?
According to Wall Street analysts Renovaro Biosciences’s price is currently Overvalued.
Does Renovaro Biosciences pay dividends?
Renovaro Biosciences does not currently pay dividends.
What is Renovaro Biosciences’s EPS estimate?
Renovaro Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renovaro Biosciences have?
Renovaro Biosciences has 143,668,370 shares outstanding.
What happened to Renovaro Biosciences’s price movement after its last earnings report?
Renovaro Biosciences reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Renovaro Biosciences?
Currently, no hedge funds are holding shares in RENB
---
Renovaro Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
RENB Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $250.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 14.0%
Last 30 Days ▼ 14.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
98.36%
12-Months-Change
Fundamentals
Return on Equity
-74.63%
Trailing 12-Months
Asset Growth
-27.72%
Trailing 12-Months
Company Description
Renovaro Biosciences
Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA.
---
Technical Analysis
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Editas Medicine
―
Fate Therapeutics
―
---